Great Point Partners LLC Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Great Point Partners LLC acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 514,659 shares of the company’s stock, valued at approximately $12,614,000. Oruka Therapeutics makes up about 3.7% of Great Point Partners LLC’s holdings, making the stock its 11th biggest holding. Great Point Partners LLC owned approximately 42.53% of Oruka Therapeutics at the end of the most recent reporting period.

Separately, FMR LLC acquired a new position in Oruka Therapeutics in the 3rd quarter worth about $114,763,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Trading Up 1.0 %

Shares of NASDAQ:ORKA opened at $18.69 on Wednesday. The company has a market capitalization of $654.13 million, a price-to-earnings ratio of -2.99 and a beta of 0.87. Oruka Therapeutics, Inc. has a 52-week low of $18.20 and a 52-week high of $53.88. The business has a 50 day moving average price of $25.86.

Wall Street Analyst Weigh In

ORKA has been the subject of a number of research reports. Leerink Partners started coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price objective for the company. TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued a “buy” rating for the company. Stifel Nicolaus began coverage on Oruka Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $49.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Monday. Finally, Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.